While the studies supporting these benefits were not initially focused on kidney health and included patients with low kidney risk, they suggest a link between GLP-1 RAs treatment and kidney protection, especially for type 2 diabetes patients with CKD18. The gene discussed is GCG; the disease is type 2 diabetes mellitus.